Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Analyst Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NUVL Stock 12 Month Forecast
Average Price Target
$116.00
▲(49.64% Upside)
| Highest Price Target$140.00 | Average Price Target$116.00 | Lowest Price Target$100.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Barclays
$100
Buy
29.00%
Upside
Reiterated
09/24/25
LifeSci Capital
$110
Buy
41.90%
Upside
Reiterated
09/22/25
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Neurocrine (NBIX)s: This morning, the company announced via SEC 8-K filing that it had completed its rolling NDA submission for ROS1 inhibitor, zidesamnib, in TKI pr e-treated ROS1+ NSCLC paen ts. Recall that NUVL submi ed under FDA Real-Time Oncology Review (RTOR), which may expedite applicaon r eview and by our previously- published esma te, leads to approval ~1-2 months before PDUFA on average. This submission represents yet another key execuon milestone for NUVL, and sets the stage for not only first approval & commercial launch, but also for likely future expansion into TKI-naive ROS1+ NSCLC (where we model $480M PoS-adjusted peak US sales in 2040 vs. $153M that same year in the pretreated seng). Per NUVL 2Q 2025 earnings (NOTE), NUVL connues t o correspond with FDA on opportunies f or line-agnosc e xpansion based on the TKI-naive cohort in ARROS-1.
Raymond James
$105
Buy
35.45%
Upside
Reiterated
09/08/25
J.P. Morgan
$111
Buy
43.19%
Upside
Reiterated
09/04/25
Guggenheim
$105→$122
Buy
57.38%
Upside
Initiated
09/03/25
Piper Sandler
$112
Buy
44.48%
Upside
Reiterated
08/26/25
Leerink Partners
$140
Buy
80.60%
Upside
Reiterated
08/12/25
H.C. Wainwright
$130
Buy
67.70%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
Goldman Sachs
―
Buy
―
Reiterated
07/03/25
Robert W. Baird
$105→$112
Buy
44.48%
Upside
Reiterated
06/25/25
Jefferies
$137
Buy
76.73%
Upside
Reiterated
12/20/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
$100
Buy
29.00%
Upside
Reiterated
09/24/25
LifeSci Capital
$110
Buy
41.90%
Upside
Reiterated
09/22/25
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Neurocrine (NBIX)s: This morning, the company announced via SEC 8-K filing that it had completed its rolling NDA submission for ROS1 inhibitor, zidesamnib, in TKI pr e-treated ROS1+ NSCLC paen ts. Recall that NUVL submi ed under FDA Real-Time Oncology Review (RTOR), which may expedite applicaon r eview and by our previously- published esma te, leads to approval ~1-2 months before PDUFA on average. This submission represents yet another key execuon milestone for NUVL, and sets the stage for not only first approval & commercial launch, but also for likely future expansion into TKI-naive ROS1+ NSCLC (where we model $480M PoS-adjusted peak US sales in 2040 vs. $153M that same year in the pretreated seng). Per NUVL 2Q 2025 earnings (NOTE), NUVL connues t o correspond with FDA on opportunies f or line-agnosc e xpansion based on the TKI-naive cohort in ARROS-1.
Raymond James
$105
Buy
35.45%
Upside
Reiterated
09/08/25
J.P. Morgan
$111
Buy
43.19%
Upside
Reiterated
09/04/25
Guggenheim
$105→$122
Buy
57.38%
Upside
Initiated
09/03/25
Piper Sandler
$112
Buy
44.48%
Upside
Reiterated
08/26/25
Leerink Partners
$140
Buy
80.60%
Upside
Reiterated
08/12/25
H.C. Wainwright
$130
Buy
67.70%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/07/25
Goldman Sachs
―
Buy
―
Reiterated
07/03/25
Robert W. Baird
$105→$112
Buy
44.48%
Upside
Reiterated
06/25/25
Jefferies
$137
Buy
76.73%
Upside
Reiterated
12/20/24
Best Analysts Covering Nuvalent
1 Month
xxx
Success Rate
7/10 ratings generated profit
Average Return
+7.41%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +7.41% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
Average Return
+16.53%
initiated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +16.53% per trade.
1 Year
Success Rate
10/16 ratings generated profit
Average Return
+38.52%
reiterated a buy rating 23 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +38.52% per trade.
2 Years
xxx
Success Rate
7/10 ratings generated profit
Average Return
+5.20%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +5.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NUVL Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
7
7
6
8
6
Buy
3
11
13
17
14
Hold
1
0
0
0
0
Sell
2
2
0
0
0
Strong Sell
0
0
0
0
0
total
13
20
19
25
20
Each month's total comprises the sum of three months' worth of ratings.
NUVL Financial Forecast
NUVL Stock Forecast FAQ
What is NUVL’s average 12-month price target, according to analysts?
Based on analyst ratings, Nuvalent’s 12-month average price target is 116.00.
What is NUVL’s upside potential, based on the analysts’ average price target?
Nuvalent has 49.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NUVL a Buy, Sell or Hold?
Nuvalent has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is Nuvalent’s price target?
The average price target for Nuvalent is 116.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $100.00. The average price target represents 49.64% Increase from the current price of $77.52.
The highest analyst price target is $140.00 ,the lowest forecast is $100.00. The average price target represents 49.64% Increase from the current price of $77.52.
What do analysts say about Nuvalent?
Nuvalent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of NUVL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.